用于肝细胞癌诊疗中肺分流分数评估及放射性栓塞的锝/钇放射性标记可生物降解凝胶微球

Tc/Y radiolabeled biodegradable gel microspheres for lung shutting fraction assessment and radioembolization in hepatocellular carcinoma theranostics.

作者信息

Dong Yi, Yin Lingling, Huang Jintao, Hu Di, Sun Jing, Zhang Zhe, Li Zhihao, Zhong Bin-Yan, Zhu Ran, Wang Guanglin

机构信息

State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, 215123, China.

Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.

出版信息

Mater Today Bio. 2024 Nov 27;29:101367. doi: 10.1016/j.mtbio.2024.101367. eCollection 2024 Dec.

Abstract

Transarterial radioembolization (TARE) is a well-established clinical therapy for the treatment of patients with intermediate to advanced hepatocellular carcinoma (HCC) or those who are ineligible for radical treatment. However, commercialized radioactive microspheres still have some issues, such as high density, complicated preparation, non-biodegradability. Furthermore, the use of different radioactive microspheres during TARE and lung shunt fraction assessment has led to inconsistencies in biodistribution in certain cases. This study employed biodegradable hyaluronic acid (HA) as the backbone and modified with bisphosphonate and methacrylic acid to prepare biodegradable gel microspheres (HAMS) using the water-in-oil emulsification and photo-crosslinking for labeling the diagnostic radionuclide of Tc and therapeutic radionuclide of Y. Both Tc radiolabeled HAMS (Tc-HAMS) and radiolabeled Y-HAMS (Y-HAMS) were highly efficient in radiolabeling and exhibited excellent radiostability and . Tc-HAMS are highly effective in assessing the LSF, while Y-HAMS, administered though TARE, are effective in inhibiting the growth of in situ HCC without any side effects. Both Tc-HAMS and Y-HAMS have promising clinical applications in HCC theranostics.

摘要

经动脉放射性栓塞(TARE)是一种成熟的临床治疗方法,用于治疗中晚期肝细胞癌(HCC)患者或那些不适合根治性治疗的患者。然而,商业化的放射性微球仍然存在一些问题,如密度高、制备复杂、不可生物降解。此外,在TARE和肺分流分数评估过程中使用不同的放射性微球,在某些情况下导致了生物分布的不一致。本研究以可生物降解的透明质酸(HA)为骨架,用双膦酸盐和甲基丙烯酸进行修饰,采用油包水乳化和光交联法制备可生物降解的凝胶微球(HAMS),用于标记Tc的诊断性放射性核素和Y的治疗性放射性核素。Tc放射性标记的HAMS(Tc-HAMS)和放射性标记的Y-HAMS(Y-HAMS)在放射性标记方面都非常高效,并且表现出优异的放射性稳定性。Tc-HAMS在评估肺分流分数方面非常有效,而通过TARE给药的Y-HAMS在抑制原位HCC生长方面有效且无任何副作用。Tc-HAMS和Y-HAMS在HCC诊疗中都具有广阔的临床应用前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56e9/11647226/c3273eeda9c1/ga1.jpg

相似文献

引用本文的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索